UBS cuts Medtronic stock price target on IPO dilution impact By Investing.com

MDT looks less like a broken story and more like a “show-me” transition where near-term EPS optics are being deliberately sacrificed to de-risk the portfolio reset. The market should care that the dilution is mechanical and front-loaded, while the strategic value creation is back-end loaded; that usually creates the most attractive entry point when the stock is already near cycle lows and multiple analysts are still revising numbers downward. The key second-order effect is that management now has more room to prioritize product mix and capital allocation over headline EPS, which can improve quality of earnings over the next 4–6 quarters even if reported growth remains muted.

The biggest loser in the near term is sentiment durability: once estimates are cut, buy-side owners tend to wait for a clean stabilization print before adding risk, which can cap rebounds for several months. But that also creates a potential squeeze setup if execution surprises even modestly on procedure growth, launch adoption, or margin stability, because positioning should be light after repeated estimate resets. The spinoff/transaction framework also tends to benefit adjacent med-tech peers by reframing valuation around focused end markets, so any rerating in MDT could spill over to slower-growth large-cap healthcare names if investors decide the sector is under-owned rather than impaired.

Contrarian view: the market may be over-anchoring on the EPS cut and underestimating the optionality from a cleaner corporate structure plus incremental product/regulatory catalysts. If the new guidance floor holds, the stock does not need a heroic growth re-acceleration to rerate; it only needs evidence that the downside to earnings is finite and that the reshaped portfolio can compound modestly above low-single-digit expectations. The risk is that more integration or portfolio-transition costs emerge over the next 1–2 quarters, which would turn this from a valuation reset into a longer de-rating cycle.